National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedMaitree R, Perez-Carrillo GJG, Shimony JS
Adaptive anatomical preservation optimal denoising for radiation therapy daily MRI.
An innovative method, adaptive anatomical preservation optimal denoising (AAPOD), was developed for optimal image denoising, i.e., to maximally reduce noise while preserving the tissue boundaries. The experimental results demonstrated that AAPOD was capable of reducing noise adaptively and optimally while avoiding tissue boundary losses.
AHRQ-funded; HS022888.
Citation: Maitree R, Perez-Carrillo GJG, Shimony JS .
Adaptive anatomical preservation optimal denoising for radiation therapy daily MRI.
J Med Imaging 2017 Jul;4(3):034004. doi: 10.1117/1.jmi.4.3.034004.
.
.
Keywords: Imaging, Treatments, Cancer, Patient Safety
Wilfond BS, Morales C, Taylor HA
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Many Phase I oncology trials include an eligibility criterion requiring potential participants to fail standard chemotherapy. The rationale for this approach is to ensure that patients do not forgo established clinical approaches. The case described in this report has the additional feature of the consultation being requested by a research participant who wanted to challenge the ethical rationale for such an eligibility criterion.
AHRQ-funded; HS000029.
Citation: Wilfond BS, Morales C, Taylor HA .
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Am J Bioeth 2017 Apr;17(4):66-67. doi: 10.1080/15265161.2017.1284934..
Keywords: Cancer, Treatments, Medication
Wilfond BS, Morales C, Taylor HA
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Many Phase I oncology trials include an eligibility criterion requiring potential participants to fail standard chemotherapy. The rationale for this approach is to ensure that patients do not forgo established clinical approaches. The case described in this report has the additional feature of the consultation being requested by a research participant who wanted to challenge the ethical rationale for such an eligibility criterion.
AHRQ-funded; HS000029.
Citation: Wilfond BS, Morales C, Taylor HA .
Should patients be required to undergo standard chemotherapy before being eligible for novel phase I immunotherapy clinical trials?
Am J Bioeth 2017 Apr;17(4):66-67. doi: 10.1080/15265161.2017.1284934..
Keywords: Cancer, Treatments, Medication